The use of CytoSorb® in a prasugrel‐loaded patient undergoing emergent coronary artery bypass graft surgery
Patients with acute coronary syndrome (ACS), failed percutaneous coronary intervention (PCI) and with an indication for emergent coronary artery bypass graft surgery (CABG) are at an increased risk of perioperative bleeding. Integration of the CytoSorb® (CS) adsorber into the cardiopulmonary bypass...
Saved in:
Published in: | Clinical case reports Vol. 11; no. 3; pp. e6990 - n/a |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
John Wiley & Sons, Inc
01-03-2023
John Wiley and Sons Inc Wiley |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Patients with acute coronary syndrome (ACS), failed percutaneous coronary intervention (PCI) and with an indication for emergent coronary artery bypass graft surgery (CABG) are at an increased risk of perioperative bleeding. Integration of the CytoSorb® (CS) adsorber into the cardiopulmonary bypass appears to bind prasugrel and minimize the risk of perioperative bleeding.
Intraoperative use of CytoSorb hemoadsorption therapy in prasugrel‐loaded patients undergoing emergency cardiac surgery might be an effective option to reduce the risk of bleeding complications. Further investigations, however, are needed for a better understanding of the precise role of the adsorber in this setting. |
---|---|
Bibliography: | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Report-1 |
ISSN: | 2050-0904 2050-0904 |
DOI: | 10.1002/ccr3.6990 |